Interestingly, these authors found that combining a C-X-C chemokine receptor (CXCR)4 antagonist with an anti-PD-1 monoclonal antibody can overcome the limitations of anti-PD-1 therapy in their osteosarcoma model. This evidence concerns the gene CXCR4 and osteosarcoma.